

Sophie Iochmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4730867/publications.pdf>

Version: 2024-02-01

9
papers

189
citations

1307366
7
h-index

1474057
9
g-index

9
all docs

9
docs citations

9
times ranked

307
citing authors

#	ARTICLE	IF	CITATIONS
1	Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor. <i>Biological Chemistry</i> , 2021, 402, 1257-1268.	1.2	5
2	Kallikrein-related peptidase 5 contributes to the remodeling and repair of bronchial epithelium. <i>FASEB Journal</i> , 2021, 35, e21838.	0.2	3
3	Structure, function, and evolution of <i>Gga</i> -AvBD11, the archetype of the structural avian-double-Î²-defensin family. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 337-345.	3.3	18
4	Kallikrein-related peptidases in lung diseases. <i>Biological Chemistry</i> , 2018, 399, 959-971.	1.2	20
5	Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway. <i>FASEB Journal</i> , 2014, 28, 740-751.	0.2	33
6	Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor. <i>Biological Chemistry</i> , 2014, 395, 1015-1025.	1.2	34
7	Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. <i>FEBS Open Bio</i> , 2013, 3, 291-301.	1.0	19
8	TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 196-208.	1.6	21
9	Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 457-467.	1.7	36